Toward predictors of survival in castration-resistant prostate cancer

Julie N. Graff; Tomasz M. Beer

doi:10.1002/cncr.25986

Toward predictors of survival in castration-resistant prostate cancer

Julie N. Graff, Tomasz M. Beer

Research output: Contribution to journal › Review article › peer-review

2 Scopus citations

Abstract

Overall survival is a widely accepted endpoint in phase 3 clinical trials of castration-resistant prostate cancer (CRPC). However, the use of this endpoint is becoming more difficult as more agents are shown to improve survival in patients with CRPC. This editorial describes the commonly used surrogates for overall survival in CRPC with a special emphasis on radiographic response.

Original language	English (US)
Pages (from-to)	3882-3884
Number of pages	3
Journal	Cancer
Volume	117
Issue number	17
DOIs	https://doi.org/10.1002/cncr.25986
State	Published - Sep 1 2011

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1002/cncr.25986

Cite this

@article{91f1fa4757e54dc697adebadafc43b98,

title = "Toward predictors of survival in castration-resistant prostate cancer",

abstract = "Overall survival is a widely accepted endpoint in phase 3 clinical trials of castration-resistant prostate cancer (CRPC). However, the use of this endpoint is becoming more difficult as more agents are shown to improve survival in patients with CRPC. This editorial describes the commonly used surrogates for overall survival in CRPC with a special emphasis on radiographic response.",

author = "Graff, {Julie N.} and Beer, {Tomasz M.}",

year = "2011",

month = sep,

day = "1",

doi = "10.1002/cncr.25986",

language = "English (US)",

volume = "117",

pages = "3882--3884",

journal = "Cancer",

issn = "0008-543X",

publisher = "John Wiley and Sons Inc.",

number = "17",

}

TY - JOUR

T1 - Toward predictors of survival in castration-resistant prostate cancer

AU - Graff, Julie N.

AU - Beer, Tomasz M.

PY - 2011/9/1

Y1 - 2011/9/1

N2 - Overall survival is a widely accepted endpoint in phase 3 clinical trials of castration-resistant prostate cancer (CRPC). However, the use of this endpoint is becoming more difficult as more agents are shown to improve survival in patients with CRPC. This editorial describes the commonly used surrogates for overall survival in CRPC with a special emphasis on radiographic response.

AB - Overall survival is a widely accepted endpoint in phase 3 clinical trials of castration-resistant prostate cancer (CRPC). However, the use of this endpoint is becoming more difficult as more agents are shown to improve survival in patients with CRPC. This editorial describes the commonly used surrogates for overall survival in CRPC with a special emphasis on radiographic response.

UR - http://www.scopus.com/inward/record.url?scp=80051939662&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051939662&partnerID=8YFLogxK

U2 - 10.1002/cncr.25986

DO - 10.1002/cncr.25986

M3 - Review article

C2 - 21391212

AN - SCOPUS:80051939662

SN - 0008-543X

VL - 117

SP - 3882

EP - 3884

JO - Cancer

JF - Cancer

IS - 17

ER -

Toward predictors of survival in castration-resistant prostate cancer

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this